Good Lifestyle

Summer is getting closer to every passing day, which has many of us launch our diet and the training routines. But while more time in the gymnasium and counting calories can work for some, losing stubborn books can be more difficult for others. It's there that drug often come. The NOVO Nordisk Ozempic diabetes drug drug and its sister medicine for weight loss, Wegovy, are the biggest names in space right now - but society is not stopping there. During the Novo Nordisk capital market day on March 7, the company announced data from an early test of its new weight loss drug, Amycretin.

In relation: Certain foods trigger the weight loss effect of the natural ozempic type, says the doctor .

The study participants who took the medication inquiry saw major results after 12 weeks, Drop 13.1% Of their body weight, biospace reported. In comparison, participants who took a placebo dropped only 1.1% of their body weight over the same period of 12 weeks. Amycretin too Batu Wegovy , because patients dropped only 6% of their body weight in a similar three -month trial, Wall Street's journal reported.

The drug differs from Wegovy because it is a pill once a day as opposed to an injection, and it targets two hormones instead of one. In addition to the glucagon type peptide -1 (GLP -1) - the intestinal hormone that Wegovy targets - Amycretine also targets amyline, a hormone in the pancreas that affects hunger, according to the Wsj .

The security results were also encouraging because the phase 1 trial has shown that AMYCritine was safe and well tolerated among the study participants, Biospace reported. According to Novo Nordisk, negative effects were similar to the company's studies on other agonists of the Glucagon type Peptide-1 receptors (GLP-1). Wegovy is known to cause mainly Gastrointestinal problems (GI), namely nausea, diarrhea, vomiting, constipation and stomach pain.

At the 12 -week brand, more than 80% of participants always took Amycretin, which is an "impressive" retention rate ,, Martin Holst Lange , MD, PHD, executive vice-president of Novo Nordisk's development, said in an interview with Reuters.

In relation: Ozempic patients say that "stops working" for weight loss - how to prevent this .

Amycretin will continue to be studied during a phase 2 test in the second half of 2024, company managers told investors yesterday. But although the latest results are exciting, it will take a while before Amycretine is available for patients.

Data from mid-term trial will not be released before around 2026, Forbes Reported, and after that, regulators will likely want an additional and in -depth test of safety and efficiency before approving Amycretine. It is also possible that the treatment does not show the same results, and Novo Nordisk could also focus on other treatments.

However, at present, the company benefits from the stellar performance of Amycretin. After the study results were announced, Novo Nordisk shares jumped 8%, Reuters reported.

"We believe that this version of data is the main engine of actions," said Barclays analysts in a note, according to the Wsj .

Novo Nordisk also tests amyline in its CAGRISEMA of weight loss combination therapy, which combines semaglutide (the active ingredient of Wegovy and Ozempic) with an analog of Amyline (a structurally similar drug) called Cagrililetide. Treatment is studied in a phase 3 trial, where it has shown weight loss and blood sugar control effects for diabetes patients than those treated with a medication or the other. AE0FCC31AE342FD3A1346EBB1F342FCB

The combination gives patients "no more bang for the male," said Lange Wsj . "It will be a real game changer."

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.